SG11202111465RA - Methods for the administration of certain vmat2 inhibitors - Google Patents
Methods for the administration of certain vmat2 inhibitorsInfo
- Publication number
- SG11202111465RA SG11202111465RA SG11202111465RA SG11202111465RA SG11202111465RA SG 11202111465R A SG11202111465R A SG 11202111465RA SG 11202111465R A SG11202111465R A SG 11202111465RA SG 11202111465R A SG11202111465R A SG 11202111465RA SG 11202111465R A SG11202111465R A SG 11202111465RA
- Authority
- SG
- Singapore
- Prior art keywords
- patient
- inhibitor
- vmat
- parkinson
- signs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845599P | 2019-05-09 | 2019-05-09 | |
| PCT/US2020/032188 WO2020227672A1 (en) | 2019-05-09 | 2020-05-08 | Methods for the administration of certain vmat2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111465RA true SG11202111465RA (en) | 2021-11-29 |
Family
ID=70919120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111465RA SG11202111465RA (en) | 2019-05-09 | 2020-05-08 | Methods for the administration of certain vmat2 inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20200397779A1 (https=) |
| EP (1) | EP3965764A1 (https=) |
| JP (2) | JP2022531696A (https=) |
| KR (1) | KR20220007105A (https=) |
| CN (1) | CN114340624A (https=) |
| AU (2) | AU2020270145A1 (https=) |
| BR (1) | BR112021020709A2 (https=) |
| CA (1) | CA3136466A1 (https=) |
| EA (1) | EA202193012A1 (https=) |
| IL (2) | IL321020A (https=) |
| JO (1) | JOP20210274A1 (https=) |
| MA (1) | MA55893A (https=) |
| MX (1) | MX2021013132A (https=) |
| PH (1) | PH12021552745A1 (https=) |
| SG (1) | SG11202111465RA (https=) |
| TW (1) | TWI850377B (https=) |
| WO (1) | WO2020227672A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3051830A1 (en) | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
| CA3076000A1 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| MA53239A (fr) | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences Inc | Procédés d'administration de certains inhibiteurs de vmat2 |
| CA3220946A1 (en) * | 2021-06-30 | 2023-01-05 | Angel S. Angelov | Valbenazine for use in the add-on treatment of schizophrenia |
| TW202322816A (zh) | 2021-08-20 | 2023-06-16 | 美商紐羅克里生物科學有限公司 | 篩選 vmat2 抑制劑之方法 |
| EP4489754A1 (en) * | 2022-03-07 | 2025-01-15 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| WO2025038959A1 (en) * | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| TW202521119A (zh) * | 2023-08-17 | 2025-06-01 | 美商紐羅克里生物科學有限公司 | 用於投與特定vmat2抑制劑之方法 |
| WO2025188830A1 (en) * | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US952A (en) | 1838-09-27 | I antoni bengini | ||
| US10065A (en) | 1853-10-04 | Improvement in machines for topping cotton jn the field | ||
| NZ725826A (en) * | 2014-05-06 | 2023-05-26 | Neurocrine Biosciences Inc | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
| KR20240125709A (ko) * | 2015-06-23 | 2024-08-19 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제 |
| CA3051830A1 (en) * | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| MA53239A (fr) * | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences Inc | Procédés d'administration de certains inhibiteurs de vmat2 |
-
2020
- 2020-05-08 MA MA055893A patent/MA55893A/fr unknown
- 2020-05-08 IL IL321020A patent/IL321020A/en unknown
- 2020-05-08 PH PH1/2021/552745A patent/PH12021552745A1/en unknown
- 2020-05-08 JP JP2021565932A patent/JP2022531696A/ja active Pending
- 2020-05-08 CN CN202080034710.XA patent/CN114340624A/zh active Pending
- 2020-05-08 EP EP20729429.9A patent/EP3965764A1/en active Pending
- 2020-05-08 EA EA202193012A patent/EA202193012A1/ru unknown
- 2020-05-08 BR BR112021020709A patent/BR112021020709A2/pt unknown
- 2020-05-08 TW TW109115397A patent/TWI850377B/zh active
- 2020-05-08 CA CA3136466A patent/CA3136466A1/en active Pending
- 2020-05-08 WO PCT/US2020/032188 patent/WO2020227672A1/en not_active Ceased
- 2020-05-08 AU AU2020270145A patent/AU2020270145A1/en not_active Abandoned
- 2020-05-08 KR KR1020217039903A patent/KR20220007105A/ko not_active Ceased
- 2020-05-08 MX MX2021013132A patent/MX2021013132A/es unknown
- 2020-05-08 SG SG11202111465RA patent/SG11202111465RA/en unknown
- 2020-08-31 US US17/007,710 patent/US20200397779A1/en not_active Abandoned
-
2021
- 2021-10-11 JO JOP/2021/0274A patent/JOP20210274A1/ar unknown
- 2021-10-21 US US17/506,883 patent/US20220040169A1/en not_active Abandoned
- 2021-11-08 IL IL287902A patent/IL287902A/en unknown
-
2024
- 2024-10-24 JP JP2024187589A patent/JP2025013963A/ja active Pending
-
2025
- 2025-10-22 AU AU2025256123A patent/AU2025256123A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020227672A1 (en) | 2020-11-12 |
| TW202108138A (zh) | 2021-03-01 |
| JOP20210274A1 (ar) | 2023-01-30 |
| US20200397779A1 (en) | 2020-12-24 |
| MA55893A (fr) | 2022-03-16 |
| PH12021552745A1 (en) | 2022-07-11 |
| AU2025256123A1 (en) | 2025-11-13 |
| EA202193012A1 (ru) | 2022-03-02 |
| IL321020A (en) | 2025-07-01 |
| MX2021013132A (es) | 2021-11-25 |
| US20220040169A1 (en) | 2022-02-10 |
| CN114340624A (zh) | 2022-04-12 |
| JP2025013963A (ja) | 2025-01-28 |
| BR112021020709A2 (pt) | 2021-12-14 |
| CA3136466A1 (en) | 2020-11-12 |
| KR20220007105A (ko) | 2022-01-18 |
| AU2020270145A1 (en) | 2021-12-23 |
| EP3965764A1 (en) | 2022-03-16 |
| IL287902A (en) | 2022-01-01 |
| JP2022531696A (ja) | 2022-07-08 |
| TWI850377B (zh) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10940141B1 (en) | Methods for the administration of certain VMAT2 inhibitors | |
| SG11202111465RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| US11026931B2 (en) | Methods for the administration of certain VMAT2 inhibitors | |
| TW202345830A (zh) | 特定vmat2抑制劑的投予方法 | |
| HK40068979B (en) | The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment | |
| HK40068979A (en) | The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment | |
| WO2025038959A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| WO2025038938A1 (en) | Valbenazine for use in the treatment of huntington's chorea |